If you bought L-glutamine for "leaky gut", immune support, post-workout recovery, lean-mass preservation, or sugar cravings, you can stop.
Twenty-seven years of trials in healthy athletes are null at the meta-analytic level. Eat enough protein and you already get 10 to 18 grams of glutamine a day from food. The 5-gram scoop is adding marginal supply to an already-adequate system.
The Protocol
Dosing breaks cleanly along the same fault line as the evidence: clinical indications have specific trial-derived protocols, and consumer indications have no evidence-supported protocol at all.
| Population | Dose | Form | Timing |
|---|---|---|---|
| Sickle cell disease age 5+ (prescriber-supervised) | 0.3 g/kg twice daily | Endari oral powder (FDA-approved) | With meals, twice daily |
| Severe burns ≥20% TBSA (hospital setting) | 0.3–0.57 g/kg/day enteral | Free L-glutamine in enteral feed | Continuous with feeds |
| Head/neck radiation oral mucositis | 10–30 g/day swish-and-swallow | Free L-glutamine oral suspension | Three times daily during radiation course |
| Pelvic/abdominal radiation enteritis | 10–30 g/day oral | Free L-glutamine | Divided across radiation course |
| ICU on parenteral nutrition (non-MOF, dietitian-managed) | 0.3 g/kg/day IV | Alanyl-L-glutamine dipeptide (Dipeptiven) | Continuous IV infusion |
| Healthy athlete (recovery / performance / immune) | Not effective | — | — |
| Healthy adult "leaky gut" / wellness | No baseline deficit | — | — |
| Critical illness with multi-organ failure | Contraindicated — DO NOT GIVE | — | — |
Forms — head-to-head
Absorption tips that actually matter
For radiation mucositis, swish-and-swallow delivery (10 grams dissolved in water, held in mouth for 30 seconds, then swallowed) maximises mucosal contact in the head-and-neck radiation field — this is the protocol from positive trials. For radiation enteritis, divide doses across the day during the radiation course. Free L-glutamine is heat- and moisture-sensitive: mix the dose right before use, do not pre-mix, do not add to hot liquids.
Safety & Interactions
The hard contraindication
Multi-organ failure ICU — high-dose IV glutamine
The Heyland 2013 REDOXS trial (N=1,223) showed 28-day mortality 32.4% with glutamine vs 27.2% without (OR 1.28, p=0.05) when IV glutamine 0.35 g/kg/day plus enteral 30 g/day was given to ICU patients with multi-organ failure. ESPEN and ASPEN guidelines now explicitly contraindicate this combination.
Drug interactions
Lactulose (hepatic encephalopathy treatment)
Glutamine reduces colonic ammonia generation and may interfere with lactulose-based treatment. Inform hepatology team.
Anticonvulsants — phenytoin, carbamazepine, phenobarbital
Theoretical glutamate-precursor seizure-threshold effect. No documented seizure cases in the supplementation literature. Monitor if escalating dose.
Chemotherapy
Pre-clinical concern about glutamine-fueled tumor metabolism. Clinical radiation enteritis and mucositis RCTs show no survival decrement, but discuss with oncologist before adding.
Contraindicated populations
- Multi-organ failure ICU: Active harm signal at supraphysiologic IV dose (Heyland 2013 REDOXS).
- Severe hepatic encephalopathy / Child-Pugh C cirrhosis: Glutamine to glutamate to ammonia metabolism may worsen encephalopathy.
- Severe renal dysfunction (eGFR <30): Increased ammonia and urea load.
- Reye's syndrome / inborn errors of urea cycle: Ammonia-handling defect.
- Pregnancy / lactation: No safety RCTs. Dietary glutamine is fine; supplementation should be avoided.
Side effects
GI upset (nausea, bloating, constipation) at 5–15% incidence at doses ≥30 g/day. Headache and dizziness at <5%. Constipation was numerically higher in the Endari pediatric subgroup of Niihara 2018. No formal Tolerable Upper Intake Level has been established by FDA, EFSA, or IOM. Practical safe ceiling is 30 g/day oral in healthy adults; up to 0.6 g/kg/day oral in burns and sickle cell with monitoring.
Strong-to-moderate clinical-outcome evidence in five catabolic medical indications. Zero clinical-outcome RCT support for consumer-marketed indications. Active harm signal at supraphysiologic IV dose in multi-organ failure.
What would change this verdict?
A single ≥150-subject double-blind RCT in healthy recreational or competitive athletes using 0.3 g/kg/day oral L-glutamine for ≥12 weeks, with primary endpoints of Wingate peak power, ultrasound-measured vastus lateralis cross-sectional area, and URI symptom-day count, showing ≥10% improvement over placebo on at least two of three primaries, would upgrade athletic-recovery conviction from LOW to MODERATE. For the healthy-adult "leaky gut" claim, a ≥200-subject RCT in non-disrupted healthy adults using 10–20 g/day for 12 weeks with validated GI symptom scale plus plasma LPS or zonulin plus lactulose/mannitol ratio. To date, every positive permeability biomarker trial has been in a baseline-disrupted population. For premium "liposomal" forms, any head-to-head outcome RCT comparing liposomal vs free L-glutamine at matched dose with clinical outcome as primary endpoint. Zero such trials exist.
Worth Your Money?
Want to stop wasting money on supplements that don't work in healthy adults? The Verdict reviews one every week. Free, evidence-graded, no affiliate links.
Subscribe to The VerdictClaims vs Evidence — See What the Research Found
What People Claim
The consumer pitch is "the most abundant amino acid in your body, depleted by stress and training, essential for gut healing and immune function." Pop-nutrition books and supplement-aisle marketing position 5–10 g/day oral glutamine as the foundation of a "leaky gut" protocol, post-workout immune insurance for athletes who don't want to get sick, an anti-catabolic during caloric deficits to preserve lean mass, and lately a sugar-craving suppressant via stable blood sugar.
The biohacker tier extends this to liposomal or "absorption-enhanced" forms costing 2–4× standard L-glutamine, with the implicit claim that bypassing first-pass intestinal extraction makes the supplement work better systemically.
The clinical pitch is real and separate. Severe burn units, sickle cell hematologists, oncology radiation teams, and ICU dietitians have a 40-year evidence base for glutamine in catabolic medicine. FDA approved Endari (oral L-glutamine 0.3 g/kg twice daily) for sickle cell disease in 2017 based on the Niihara phase III trial. ESPEN 2019 critical-care guidelines support alanyl-L-glutamine dipeptide in parenteral nutrition. MASCC/ISOO oral mucositis guidelines incorporate oral L-glutamine for head-and-neck radiation patients.
What the Evidence Actually Shows
| Claimed Benefit | Conviction | Effect Size | Key Study |
|---|---|---|---|
| Sickle cell pain crisis reduction (age ≥5, prescriber-supervised) | HIGH | 25% relative reduction in crises (3.0 vs 4.0 over 48 wk, p=0.005) | Niihara 2018 NEJM N=230 phase III pivotal |
| Severe burn mortality + infection reduction (enteral) | MOD-HIGH | Mortality RR 0.75 (p=0.02), infection RR 0.71 (p=0.001), TSA-confirmed | Tan 2023 PMID 37114912 SR+MA+TSA 19 RCTs N=1,389 |
| ICU on PN excluding MOF (alanyl-glutamine dipeptide) | MODERATE | Mortality RR 0.71 (95% CI 0.55–0.93, p=0.01) | Stehle 2017 PMID 28361751 SR+MA 14 RCTs N=587 |
| Head/neck radiation oral mucositis (severe grade ≥3) | MODERATE | RR 0.27 (95% CI 0.16–0.46, p<0.001) | Sayed 2021 PMID 34240498 SR+MA 9 RCTs N=702 |
| Pelvic/abdominal radiation enteritis | MODERATE | RR 0.71 (95% CI 0.56–0.88, p=0.002) | Tao 2017 PMID 28427169 SR+MA 13 RCTs N=1,029 |
| Intestinal permeability biomarker (LMR) — barrier-disrupted populations only | BIOMARKER ONLY | SMD −0.61 (95% CI −1.05 to −0.17, p<0.01) higher-dose subgroup | Pang 2024 PMID 39397201 SR+MA 9 RCTs |
| IBD clinical outcome (Crohn's CDAI, UC relapse) | WEAK | NULL on disease activity despite biomarker improvement | Akobeng 2002 + Benjamin 2012 Cochrane-aged |
| Healthy adult "leaky gut" / gut wellness | NO EVIDENCE | No RCT in non-disrupted populations | — |
| Athletic performance (TTE, strength, hypertrophy) | DEBUNKED | NULL (TTE WMD +1.2 min, p=0.13) | Ramezani Ahmadi 2019 PMID 29784526 SR+MA 22 RCTs N=624 |
| Athletic body composition (FFM, fat mass) | DEBUNKED | NULL (FFM +0.21 kg, p=0.34) | Ramezani Ahmadi 2019 |
| Athletic immune function (URI, IL-6, CD4/CD8) | DEBUNKED | NULL; foundational Castell 1996/1997 series never replicated in 27 years | Ramezani Ahmadi 2019 |
| Post-exercise DOMS / glycogen resynthesis | WEAK | Small individual trials inconsistent; no SR-level positive signal | — |
| Sugar craving / appetite suppression | NO EVIDENCE | No controlled RCT | — |
| Multi-organ failure ICU (high-dose IV) | ACTIVE HARM | 28-day mortality OR 1.28 (95% CI 1.00–1.64, p=0.05) | Heyland 2013 REDOXS NEJM N=1,223 |
| Hard CV outcomes / cancer prevention / longevity | NONE | No RCT | — |
The Full Picture — Mechanism, Debate & Nuance
How It Works
L-Glutamine is the most abundant free amino acid in plasma (around 600 micromol/L) and in skeletal muscle, where it accounts for roughly 60% of the free intramuscular amino acid pool. The body synthesizes 50–80 g/day endogenously, mostly in skeletal muscle and lung tissue, and gets another 5–10 g/day from dietary protein. The three highest consumers in absolute terms are the enterocytes lining the small intestine (which use glutamine as their primary fuel via glutaminolysis to alpha-ketoglutarate, supporting tight-junction integrity and IgA production), the immune cells (lymphocytes and macrophages use glutamine for proliferation and reactive-oxygen-species handling), and the kidneys (glutamine donates ammonia for acid-base buffering).
In severe catabolic stress — sepsis, ≥20% body-surface burns, major surgery, prolonged exhaustive exercise, sickle cell crisis — endogenous synthesis cannot keep up with demand. Plasma glutamine drops. The amino acid becomes "conditionally essential" in this state. This is the entire mechanistic rationale for clinical supplementation, and it is the reason every positive clinical-outcome trial sits in a catabolic-medicine population.
In sickle cell disease the mechanism is redox-related rather than barrier-related. Sickled erythrocytes have a depleted NAD redox ratio and elevated oxidative stress. L-glutamine is a precursor for NAD synthesis via the salvage pathway. Niihara's pre-clinical work showed glutamine supplementation raises erythrocyte NAD redox ratio in sickle cell patients, which provided the rationale for the 0.3 g/kg twice-daily dosing in the phase III pivotal trial.
In gut barrier function, glutamine maintains tight-junction protein expression (ZO-1, occludin, claudin) via mTORC1 signaling and heat shock protein induction in enterocytes. This explains why intestinal permeability biomarkers move with supplementation in barrier-disrupted populations. The catch is that healthy adults eating adequate protein already have an intact barrier and adequate enterocyte glutamine. The "leaky gut" supplementation rationale collapses without demonstrated baseline disruption first.
The Debate
REDOXS harm signal vs Stehle PN benefit — population matters
Population differs. Multi-organ failure is the subgroup where high plasma glutamine becomes a substrate problem (elevated baseline glutamine plus IV supraphysiologic dose drives glutamate and ammonia overload). Non-MOF ICU on PN has the opposite physiology — depleted glutamine, intestinal villus atrophy from absent enteral feeding. The lesson is route plus population, not "glutamine is bad".
Permeability biomarker moves, clinical outcome doesn't follow
Biomarker-vs-clinical-outcome dissociation. Glutamine reliably moves the permeability biomarker but does not consistently move the clinical disease endpoint. Same pattern as MCT oil acute ketonemia vs cognitive outcome, krill oil omega-3 index vs joint pain, phosphatidylserine EEG vs healthy-adult cognition, CoQ10 plasma levels vs CV mortality.
27 years of "glutamine for athletes" — what the meta-analysis says
Castell trials were the foundational "glutamine for immunity" series. Never replicated at trial-grade scale in subsequent 27 years. The Newsholme glutamine-anti-fatigue hypothesis became consumer marketing despite the meta-analysis not supporting it. Same pattern as Starks 2008 N=10 phosphatidylserine cortisol attenuation never-replicated in 17 years.
Honest Limitations
Indication transfer error is the dominant translational failure
Every positive clinical-outcome trial is in a population with depleted plasma glutamine, disrupted barrier, and active catabolic stress (sickle cell crisis, severe burn, ICU on PN, radiation tissue injury). Healthy adults eating adequate protein have normal plasma glutamine, intact barrier, and no catabolic stress. The mechanism doesn't extrapolate.
The Newsholme hypothesis is consumer marketing, not evidence
The 1985 glutamine-anti-fatigue hypothesis plus the Castell 1996/1997 athlete-URI series became the marketing scaffold. Ramezani Ahmadi 2019 pooled 22 RCTs in 624 healthy athletes. Null across performance, body composition, and immune endpoints. The hypothesis lives in the supplement aisle, not in the evidence base.
Premium "liposomal" forms are mechanistically incoherent for gut indications
First-pass enterocyte extraction (~67% per Déchelotte 1991 tracer studies) is the mechanism for radiation enteritis, mucositis, and IBD permeability indications. If a premium form bypasses the enterocyte, it bypasses the only tissue with reliable clinical-outcome evidence for oral glutamine. Buying a premium form is buying a marketing chart, not a clinical benefit.
Combo-product unisolatability
A large fraction of "glutamine" products are BCAA+glutamine or HMB+arginine+glutamine combos. The glutamine-attributable effect is not isolable in any of these. Same trap as PS+caffeine, PS+PA, GLA+evening primrose blends, krill oil's omega-3+astaxanthin combination.
The Nuance
' width='800' height='400'/%3E%3C/svg%3E)
Dietary protein is the food-first alternative. Protein contains roughly 5–8% glutamine by weight. An athlete eating 1.6–2.2 g/kg/day protein consumes 10–18 g/day glutamine from dietary protein alone. The consumer 5–10 g/day scoop is marginal redundancy in this population. If protein intake is inadequate, the better first dollar goes to whey protein at adequate intake, not to a glutamine top-up.
Cost ranges by indication. Free L-glutamine powder runs £8–15/month at 10 g/day consumer doses, £15–35/month for the 30 g/day radiation-indication course. Endari (sickle cell prescription) is insurance-billed; NHS funding pathway varies. Premium "liposomal" forms run 2–4× standard with zero head-to-head outcome RCT evidence.
Who genuinely benefits. Ranked by evidence strength: (1) sickle cell disease patients ≥5 years on Endari with prescriber supervision, (2) severe burn patients ≥20% TBSA in hospital setting on enteral feed, (3) head/neck radiation patients during the course of radiation, (4) pelvic/abdominal radiation patients during the course of radiation, (5) ICU patients on parenteral nutrition without multi-organ failure under ICU dietitian management. Healthy adults are not on this list.
One brain MRS footnote. Twelve brain ¹H-MRS meta-analyses appeared in the literature sweep, measuring endogenous brain glutamate-glutamine cycle in depression, bipolar, schizophrenia, ADHD, and Alzheimer's. These are NOT supplementation studies. They are biomarker studies of the brain's own glutamate-glutamine signal. Oral L-glutamine does not cross the blood-brain barrier in meaningful amounts; it is largely converted to glutamate, ammonia, glucose, or citrulline at the enterocyte first-pass. Anyone citing brain glutamate MRS studies as a rationale for oral L-glutamine supplementation is making a mechanism category error.
Sources
- Niihara Y, Miller ST, Kanter J, et al. (2018). A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med 379(3):226–235. DB-RCT N=230; 25% relative reduction in pain crises (3.0 vs 4.0 over 48 wk, p=0.005). FDA-approved as Endari 2017.
- Pang Y, Zheng Y, Yang N, et al. (2024). Systematic review and meta-analysis of clinical trials on the effects of glutamine supplementation on intestinal permeability. Amino Acids 56(1):66. PMID 39397201. 9 RCTs; LMR SMD −0.61 (p<0.01) higher-dose subgroup, non-significant overall.
- Heyland D, Muscedere J, Wischmeyer PE, et al. (2013). A randomized trial of glutamine and antioxidants in critically ill patients (REDOXS). N Engl J Med 368(16):1489–1497. DB-RCT N=1,223; 28-d mortality OR 1.28 (p=0.05) — active harm signal in multi-organ failure.
- Stehle P, Ellger B, Kojic D, et al. (2017). Glutamine dipeptide-supplemented parenteral nutrition improves clinical outcomes of critically ill patients. Clin Nutr ESPEN 17:75–85. PMID 28361751. 14 RCTs N=587; mortality RR 0.71 (p=0.01).
- Tan C, Zhu F, Pan P, et al. (2023). Efficacy of glutamine supplementation in severe adult burn patients: a systematic review with trial sequential meta-analysis. Crit Care Med 51(8):1086–1095. PMID 37114912. 19 RCTs N=1,389; mortality RR 0.75 (p=0.02), infection RR 0.71 (p=0.001), TSA-confirmed.
- Sayed R, El Wakeel L, Saad AS, et al. (2021). Glutamine for prevention and alleviation of radiation-induced oral mucositis in head and neck cancer. Head Neck 43(10):3266–3279. PMID 34240498. 9 RCTs N=702; severe mucositis RR 0.27 (p<0.001).
- Tao KM, Li XQ, Yang LQ, et al. (2017). Therapeutic role of glutamine in management of radiation enteritis: a meta-analysis of 13 randomized controlled trials. Oncotarget 8(12):20736–20744. PMID 28427169. 13 RCTs N=1,029; enteritis RR 0.71 (p=0.002).
- Ramezani Ahmadi A, Rayyani E, Bahreini M, et al. (2019). Effect of glutamine supplementation on athletic performance, body composition, and immune function: a systematic review and meta-analysis. Clin Nutr 38(3):1076–1091. PMID 29784526. 22 RCTs N=624; all primary outcomes null.
- Wischmeyer PE, Dhaliwal R, McCall M, et al. (2014). Parenteral glutamine supplementation in critical illness: a Cochrane systematic review. Cochrane Database Syst Rev CD010050. PMID 25199493. 53 RCTs N=4,671.
- Cruzat V, Rogero MM, Noelke C, Tirapegui J. (2018). Glutamine: metabolism and immune function, supplementation and clinical translation. Nutrients 10(11):1564. PMC6266414. Foundational mechanism and clinical translation review.